Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Net Margin (2020 - 2025)

Historic Net Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 10.48%.

  • Cytek Biosciences' Net Margin fell 123000.0% to 10.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.51%, marking a year-over-year decrease of 14600.0%. This contributed to the annual value of 3.0% for FY2024, which is 32900.0% up from last year.
  • Cytek Biosciences' Net Margin amounted to 10.48% in Q3 2025, which was down 123000.0% from 12.24% recorded in Q2 2025.
  • Cytek Biosciences' 5-year Net Margin high stood at 16.78% for Q4 2024, and its period low was 27.5% during Q1 2025.
  • In the last 5 years, Cytek Biosciences' Net Margin had a median value of 5.76% in 2022 and averaged 5.49%.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -175700bps in 2023, then skyrocketed by 152800bps in 2024.
  • Over the past 5 years, Cytek Biosciences' Net Margin (Quarter) stood at 1.01% in 2021, then soared by 625bps to 7.3% in 2022, then rose by 29bps to 9.45% in 2023, then skyrocketed by 78bps to 16.78% in 2024, then crashed by -162bps to 10.48% in 2025.
  • Its last three reported values are 10.48% in Q3 2025, 12.24% for Q2 2025, and 27.5% during Q1 2025.